Keuangan Natera, Inc. (NTRA)
NASDAQ · Healthcare · Medical - Diagnostics & Research · Karyawan: 6.138 · CEO: Steven Leonard Chapman
- Harga
- $414,30 -4,98%
- Kapitalisasi pasar
- $59,7 M
- Nilai perusahaan
- $58,9 M
- Laporan terakhir
- Q2 '26 diajukan 2026-08-07
- Laporan berikutnya
- 2026-11-05 Estimasi EPS: -$0,28
Valuasi & angka utama
- Kapitalisasi pasar
- $59,7 M EV $58,9 M
- Pendapatan
- $2,71 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +26% Konsensus FY2026
- Margin laba
- -7,1% Laba bersih / pendapatan, TTM
- P/E
- -304,6× Forward -284,9× (FY2026)
- P/S
- 22,1× Harga / penjualan, TTM
- EV / EBITDA
- -329,4× TTM
- Arus kas bebas
- $71,7 jt 12 bulan terakhir
- Laba bersih
- -$192 jt 12 bulan terakhir
- Estimasi pendapatan
- $2,91 M Konsensus FY2026
- Laba
- 2026-11-05 Estimasi pendapatan: $708 jt
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-06): pendapatan melampaui 13,8%, EPS melampaui 4,8%Pendapatan $753 jt vs $661 jt yang diharapkan (+13,8%); EPS -$0,47 vs -$0,49 (+4,8%).
- Pertumbuhan pendapatan menguat: 37,7% yoyPendapatan Q2 '26: $753 jt, rata-rata empat kuartal sebelumnya: 36,4%.
- Margin operasional -10,7% (TTM), dibanding tahun lalu: +4,2 poinLaba operasional tumbuh 1,3%, pendapatan tumbuh 37,8%.
- Capex: 5,8% dari pendapatan (tahun lalu 4,2%)$157 jt diinvestasikan dalam 4 kuartal terakhir (+90,6% dibanding tahun sebelumnya). Arus kas bebas: $71,7 jt.
- Jumlah saham dilusian naik dalam setahun: 5,1%Saham dilusian pada Q2 '26: 143 jt, setahun sebelumnya: 136 jt.
- Kas neto: $853 jtKas + investasi jangka pendek: $1,09 M, utang termasuk sewa: $238 jt; tahun lalu kas neto: $820 jt.
Kuartal terakhir: Q2 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q2 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $753 jt | $547 jt | +37,7% |
| Margin kotor | 64,5% | 63,5% | +1,0 poin |
| Laba operasional | -$75,8 jt | -$110 jt | +31,3% |
| Margin operasional | -10,1% | -20,2% | +10,1 poin |
| Laba bersih | -$67 jt | -$101 jt | +33,7% |
| EPS dilusian | -$0,47 | -$0,74 | +36,5% |
| Arus kas operasional | $54,8 jt | $37,6 jt | +45,8% |
| Capex | $63,4 jt | $25,9 jt | +144,9% |
| Arus kas bebas | -$8,64 jt | $11,7 jt | -174,0% |
| R&D | $228 jt | $146 jt | +55,8% |
| Kompensasi berbasis saham | $103 jt | $93,4 jt | +10,4% |
Dilaporkan vs konsensus
2026-08-06| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $753 jt | $661 jt | +13,8% |
| EPS (basis konsensus) | -$0,47 | -$0,49 | +4,8% |
Dari laporan 2026-08-06 untuk Q2 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Product | $748 jt | +37,4% | 100,0% | $2,69 M | +13,9% | |
| Licensing and other | – | – | – | – | – | |
| Oncology | $300 rb | – | 0,0% | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q2 '26 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $739 jt | – | 98,2% | – | – | |
| United States | – | – | – | – | – | |
| EMEA | $9,02 jt | – | 1,2% | – | – | |
| Europe, Middle East, India, Africa | – | – | – | – | – | |
| Americas, excluding U.S. | – | – | – | – | – | |
| Asia Pacific and Other | – | – | – | – | – | |
| Americas, Excluding United States | $2,22 jt | – | 0,3% | – | – | |
| Asia Pacific And Other | $2,05 jt | – | 0,3% | – | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- $228 jt
- Capex
- -$157 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- -$16 jt
- Utang neto diterbitkan
- $0
- Kompensasi berbasis saham
- $381 jt
- Arus kas bebas
- $71,7 jt
- Dikembalikan ke pemegang saham / FCF
- -0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -304,6× | – | – |
| EV / EBITDA | -329,4× | – | – |
| EV / Penjualan | 21,7× | 9,9× | 4,8× – 14,0× |
| Harga / FCF | 832,9× | 286,1× 2 dari 5 tahun | 285,1× – 287,1× |
| Harga / Nilai buku | 32,6× | 12,6× | 5,6× – 18,3× |
| Imbal hasil FCF | 0,1% | -4,0% | -12,1% – 0,4% |
| Imbal hasil modal yang diinvestasikan | -10,0% | -30,6% | -46,2% – -11,1% |
| Imbal hasil ekuitas | -11,7% | -46,9% | -77,6% – -12,2% |
Analis
Target konsensus $386,00 (-6,8%)
rentang $245,00 – $500,00 · peringkat Buy
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $2,91 M | +26,2% | -$1,45 | +4,3% | -284,9× | 13 |
| FY2027 | $3,52 M | +20,9% | -$0,37 | +74,6% | -1.122,2× | 12 |
| FY2028 | $4,26 M | +21,1% | $1,27 | +445,3% | 325,0× | 16 |
| FY2029 | $5,13 M | +20,5% | $2,14 | +68,1% | 193,3× | 13 |
| FY2030 | $6,19 M | +20,5% | $3,65 | +70,2% | 113,6× | 13 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 235 angka yang ditandai Natera, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| $890 rb | $1,03 jt | -13,5% | – | – | – | |
| Accounts Payable, Current | $75,2 jt | $36,9 jt | +103,8% | $33,2 jt | $34,9 jt | -5,1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $422 jt | $309 jt | +36,5% | $297 jt | $314 jt | -5,6% |
| Accounts Receivable, Allowance for Credit Loss | $8,02 jt2025-12-31 | $7,26 jt | +10,5% | $8,02 jt | $7,26 jt | +10,5% |
| Accounts Receivable, Allowance for Credit Loss, Current | $6,53 jt | $7,82 jt | -16,6% | $8,02 jt | $7,26 jt | +10,5% |
| Accounts Receivable, Credit Loss Expense (Reversal) | – | – | – | $1,61 jt | $1,28 jt | +25,6% |
| Accrued Bonuses, Current | $48,9 jt2025-12-31 | $32,2 jt | +51,8% | $48,9 jt | $32,2 jt | +51,8% |
| Accrued Insurance | $9,66 jt | $9,7 jt | -0,4% | $9,51 jt | $11,3 jt | -15,7% |
| Accrued Marketing Costs, Current | $26,2 jt | $16,6 jt | +58,4% | $20,2 jt | $16,5 jt | +22,2% |
| Accrued Professional Fees | $53,8 jt | $84,7 jt | -36,5% | $56,1 jt | $54,2 jt | +3,4% |
| Accrued Sales Commission, Current | $19,4 jt2025-12-31 | $14,2 jt | +36,5% | $19,4 jt | $14,2 jt | +36,5% |
| Accrued Vacation, Current | $4,7 jt2025-12-31 | $3,83 jt | +22,8% | $4,7 jt | $3,83 jt | +22,8% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $133 jt | $91,7 jt | +45,5% | $111 jt | $78,4 jt | +41,7% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$108 rb | -$287 rb | +62,4% | -$258 rb | -$344 rb | +25,0% |
| Additional Paid in Capital, Common Stock | $4,75 M | $3,98 M | +19,3% | $4,49 M | $3,76 M | +19,3% |
| Advertising Expense | – | – | – | $10,6 jt | $2,3 jt | +360,9% |
| Amortization of Debt Discount (Premium) | – | – | – | $991 rb2024-12-31 | $1,29 jt | -23,3% |
| Amortization of Intangible Assets | $5,7 jt | $0 | – | $3,9 jt | $1 jt | +290,0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | -972 rb | -553 rb | -75,8% | 12,5 jt | 14,5 jt | -14,1% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $102 jt | $94,1 jt | +8,4% | $357 jt | $277 jt | +29,1% |
| APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition | $0 | $812 rb | -100,0% | $32,9 jt | $24,1 jt | +36,6% |
| Asset Impairment Charges | $0 | $0 | – | $02021-12-31 | – | – |
| Assets | $2,66 M | $1,76 M | +51,2% | $2,4 M | $1,66 M | +44,4% |
| Assets, Current | $1,66 M | $1,43 M | +15,9% | $1,5 M | $1,38 M | +8,8% |
| Assets, Fair Value Disclosure | $1,11 M | – | – | – | – | – |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | -$5,57 jt | $0 | – | – | – | – |
| Business Combination, Contingent Consideration, Liability | $121 jt | – | – | – | – | – |
| Business Combination, Contingent Consideration, Liability, Current | $22,8 jt | – | – | $21,6 jt | – | – |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $97,7 jt | – | – | $96,8 jt | – | – |
| Capitalized Computer Software, Net | $31,2 jt2025-12-31 | $17,1 jt | +82,5% | $31,2 jt | $17,1 jt | +82,5% |
| Cash and Cash Equivalents, Fair Value Disclosure | $1,09 M | – | – | – | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $1,09 M | $1 M | +9,1% | $1,08 M | $946 jt | +13,8% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | $34,7 jt2025-12-31 | $52,7 jt | -34,2% | $131 jt | $303 jt | -57,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $3,57 jt | $26,3 jt | -86,4% | – | – | – |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 750 jt | 750 jt | 0,0% | 750 jt | 750 jt | 0,0% |
| Common Stock, Shares, Issued | 144 jt | 137 jt | +5,0% | 140 jt | 133 jt | +5,3% |
| Common Stock, Shares, Outstanding | 144 jt | 137 jt | +5,0% | 140 jt | 133 jt | +5,3% |
| Common Stock, Value, Issued | $14 rb | $14 rb | 0,0% | $14 rb | $12 rb | +16,7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$66,9 jt | -$101 jt | +33,8% | -$208 jt | -$188 jt | -10,9% |
| Contract with Customer, Liability | $56,6 jt | $38,1 jt | +48,8% | $42 jt | $36,6 jt | +14,7% |
| Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized | -$11,8 jt | -$3,93 jt | -200,6% | -$25,9 jt | -$20,9 jt | -23,8% |
| Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress | -$11,8 jt | -$5,49 jt | -114,5% | -$19,2 jt | -$13,7 jt | -40,2% |
| Contract with Customer, Liability, Current | $40,6 jt | $21,6 jt | +88,2% | $24,9 jt | $19,8 jt | +26,1% |
| Contract with Customer, Liability, Noncurrent | $16,1 jt | $16,5 jt | -2,5% | $17,1 jt | $16,8 jt | +1,3% |
| Costs and Expenses | $829 jt | $657 jt | +26,1% | $2,62 M | $1,92 M | +36,3% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $200 rb | – | – |
| Debt Conversion, Converted Instrument, Amount | – | – | – | $287 jt2024-12-31 | – | – |
| Debt Instrument, Collateral Amount | $150 jt | $150 jt | 0,0% | $150 jt | $150 jt | 0,0% |
| Debt Securities, Available-for-sale | $1,09 M | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | $0 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | $0 | – | – | – | – | – |
| Debt Securities, Available-for-sale, Allowance for Credit Loss | $0 | $0 | – | $02024-12-31 | $0 | – |
| Debt Securities, Available-for-sale, Amortized Cost | $1,09 M | – | – | – | – | – |
| Debt Securities, Available-for-sale, Current | $1 jt2025-09-30 | $29,5 jt | -96,6% | – | – | – |
| Debt Securities, Available-for-sale, Unrealized Loss Position | – | – | – | $17,7 jt2024-12-31 | $115 jt | -84,7% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | – | – | – | $330 rb2024-12-31 | $2,75 jt | -88,0% |
| Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | – | – | – | 6 position2024-12-31 | 19 position | -68,4% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $51,7 jt | – | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $9 jt | – | – |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-02